Introduction
============

Septic arthritis (SA) is an acute infectious disease of the skeletal system caused by pyogenic bacteria. Acute SA is a potentially devastating disease in childhood that is responsible for significant morbidity and even mortality (1%--15%).[@b1-dddt-12-2277] The higher incidence of infection in those of a younger age carries the great concerns with this issue. Early application of effective antibiotics is the key to the treatment of SA, but there are still 10%--25% of children with joint dysfunction, abnormal bone growth, and other sequelae even after the bacteria have been eradicated with antimicrobial treatment.[@b2-dddt-12-2277],[@b3-dddt-12-2277]

The sequelae of joint infection in children following anti-infective therapy may be related to the abnormal inflammatory response of the host immune system to the pathogen.[@b4-dddt-12-2277] These pro-inflammatory cytokines in the joint cavity, such as interleukin (IL)-1, tumor necrosis factor, IL-17, and IL-6 stimulating osteoclast differentiation lead to subsequent bone reabsorption and cartilage degradation.[@b5-dddt-12-2277] The results of animal experiments show that it is necessary to carry out anti-inflammatory treatment to inhibit the inflammatory reaction and reduce the destruction of articular cartilage on the basis of effective antibiotic treatment of SA.[@b6-dddt-12-2277]--[@b8-dddt-12-2277] Glucocorticoid therapy has been one well-established method of reducing inflammation reaction for decades.[@b9-dddt-12-2277] Corticosteroid administration and sequential antibiotic therapy have beneficial effects in mouse models on treatment to inhibit the inflammatory reaction.[@b8-dddt-12-2277] These findings were supported by clinical studies in children with SA. The first, by Arti et al,[@b10-dddt-12-2277] showed that routine antibiotic therapy and intravenous dexamethasone can reduce the clinical symptoms, accelerate recovery, and restore daily activities in children with SA. The second study was conducted by Odio et al[@b11-dddt-12-2277] in 123 patients using a double-blind, randomized, placebo-controlled study design. Odio et al[@b11-dddt-12-2277] found that a 4-day course of low-dose dexamethasone reduced residual joint dysfunction and obviously shortened the duration of symptoms in children with SA. Although, the benefits of corticosteroids as adjunctive therapy with antibiotics in the treatment of children with SA are encouraging, supplemental glucocorticoid therapy is still a debatable point.[@b12-dddt-12-2277],[@b13-dddt-12-2277] For example, chronic use of steroids in children may lead to adrenal insufficiency, growth retardation, and osteoporosis.[@b13-dddt-12-2277] Furthermore, treatment with glucocorticoids may hide symptoms of infection.[@b14-dddt-12-2277] A recent systematic review confirms that further studies are needed to clarify the results.[@b15-dddt-12-2277] Therefore, we necessarily performed a meta-analysis to investigate the effectiveness of adjunctive administration of corticosteroids in the treatment of SA in children.

Materials and methods
=====================

The present study was completed according to the preferred reporting items for systematic review and meta-analyses (PRISMA) statement (Checklist S1).

Literature and search strategy
------------------------------

The electronic databases, including Cochrane Library, Medline, PubMed, Embase, ScienceDirect, and other databases were retrieved to identify the publications randomized controlled trials (RCTs) and randomized cohort study (RCS) exploring the adjunctive administration of dexamethasone to antibiotic therapy in the clinical course of SA in children from the inception of electronic databases to January 2018. Structured search strategies were used in combination, according to Boolean logic: (steroids OR corticosteroids OR glucocorticoids OR dexamethasone) AND (infectious arthritis OR bacterial arthritis OR SA OR suppurative arthritis). In addition, the research on the appraisal reference list was manually reviewed for other potential trials that should be included. The process was iterated until no further articles could be determined. The meta-analysis was based on acknowledged PRISMA guidelines (the prioritized reported items for systematic review and meta-analysis).

Inclusion and exclusion criteria
--------------------------------

If the article met the following criteria in accordance with PICOS, the article was considered to be included in the current meta-analysis: 1) population: children with SA; 2) intervention: corticosteroids as adjunctive therapy with antibiotics; 3) comparison intervention: dexamethasone group to placebo group; 4) outcome measures, 1 or more of the following outcomes were reported: the days of hospitalization, the days of intravenous antibiotics treatment, the days of oral antibiotics treatment, and the days to normalization of C-reactive protein (CRP); 5) an official published full-text English-written RCTs or RCS. Exclusion criteria: 1) Non-English language publications, case reports, comments, letters, editorials, protocols, guidelines, and review papers were excluded; 2) animal studies were excluded; 3) articles were also excluded if they are concentrated on non-intravenous application of corticosteroids. A clear description on how the diagnosis of SA is demonstrated in the articles: 1) acute symptom of joint (fever, solitary joint pain, swelling, tenderness, limited range of motion, limp, or afebrile neonate with extremity disuse); 2) elevations of CRP or erythrocyte sedimentation rate; and 3) a turbid purulent appearance of joint fluid and an elevated white blood cell count.

Data extraction and outcome measures
------------------------------------

Two of the reviewers independently extracted data from the included studies. The following essential information was captured: first author name, publication year, sample size, study design, and outcomes. Other relevant data such as patient characteristics and literature quality score were also extracted from individual studies. The extracted data: median, range and size of the trial, and mean difference (MD) and SD were input into the designed standardized table. When there were differences in opinion, another author had the final decision. The outcome measurements were the number of days of hospitalization, both intravenous and oral antibiotics treatment, and the number of days to normalization of CRP. Complications included incidence of infection, fracture, nerve and vascular injury, and thrombosis. All results of the meta-analysis are presented in [Table 1](#t1-dddt-12-2277){ref-type="table"}.

Quality assessment and statistical analysis
-------------------------------------------

Tools from Cochrane Bone, the Joint and Muscle Trauma Group and the methodological index for non-randomized studies (MINORS) were used to evaluate the quality of the included studies. The literature quality evaluation was conducted separately by two reviewers. Consensus was reached through consultation for divergence. We used STATA version 11.0 (Stata Corporation) for statistical analyses. When *I*^2^\>50%, we considered the data to have obvious heterogeneity, and we conducted a meta-analysis using a random-effect model according to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Otherwise, the fixed-effect model was performed. The results of the continuous outcomes (the number of days of hospitalization, intravenous and oral antibiotics treatment, and the number of days to normalization of CRP) were expressed as the MD with 95% CIs. For discontinuous variable outcomes, a risk difference or relative risk with 95% CIs was applied for the assessment.

Results
=======

Search results
--------------

The selection process is illustrated in [Figure 1](#f1-dddt-12-2277){ref-type="fig"}, the original database (Cochrane Library, Medline, PubMed, Embase, and ScienceDirect) search yielded 236 records. Of them, 32 articles were eliminated because of duplication. Another 186 articles were excluded for various reasons (unavailable data, case report, reviews, and irrelevant articles). The remaining 18 articles were reviewed in their entity. We excluded 14 articles, because they did not compare dexamethasone group to placebo group in children with SA. Finally, four articles[@b10-dddt-12-2277],[@b11-dddt-12-2277],[@b14-dddt-12-2277],[@b16-dddt-12-2277] were included in our meta-analysis.

Risk of bias assessment
-----------------------

The scale of Cochrane Bone and the Joint and Muscle Trauma Group were used to evaluate the quality of the included studies of RCTs. The details are presented in [Figure 2](#f2-dddt-12-2277){ref-type="fig"}. The scores of one RCS evaluated by the MINORS quality assessment were 18. [Table 2](#t2-dddt-12-2277){ref-type="table"} summarizes more details of the quality assessment for RCS.

Study characteristics
---------------------

Demographic characteristics and details concerning the literature type of the included studies are summarized in [Table 3](#t3-dddt-12-2277){ref-type="table"}. The studies included in the meta-analysis were from 2003 to 2015 and involved 348 patients (141 were treated with dexamethasone and 207 with placebo).

Outcomes of meta-analysis
-------------------------

### Number of days of hospitalization

Two studies provided the number of days of hospitalization. A significant heterogeneity was found (*I*^2^=0.0%, *P*=0.524), and we used fixed-effect model. The results show 56 cases in the experimental and 120 in the control groups. The number of hospitalization days between the experimental group and the control group was statistically significant (MD = −4.226, 95% CI: −4.785 to −3.667, *P*=0.001, [Figure 3](#f3-dddt-12-2277){ref-type="fig"}). The present meta-analysis shows that dexamethasone as adjunctive therapy with antibiotics can shorten the days of hospitalization in children with SA.

### Number of days to normalization of CRP

Three studies provided the number of days to normalization of CRP. No obvious heterogeneity was observed, and a fixed model was used (*I*^2^=0.0%, *P*=0.728). The results show 111 cases in the experimental and 177 in the control groups. There was a significant difference in the number of days to normalization of CRP between the experimental and the control groups (MD = −3.075, 95% CI: −3.362 to −2.788, *P*=0.001, [Figure 4](#f4-dddt-12-2277){ref-type="fig"}). The present meta-analysis shows that the reduction of CRP in dexamethasone-treated patients was significantly faster than the reduction of CRP in patients in the placebo group.

### Number of days of intravenous antibiotic treatment

Three studies provided the number of days of intravenous antibiotic treatment. We observed that the result did not show significant heterogeneity, and randomize-effect was used (*I*^2^=61.8%, *P*=0.073). The results show 111 cases in the experimental, and 177 in the control groups. There was a significant difference in the number of days of intravenous antibiotic treatment between the experimental and the control groups (MD = −3.593, 95% CI: −4.825 to −2.361, *P*=0.001, [Figure 5](#f5-dddt-12-2277){ref-type="fig"}). The present meta-analysis shows that dexamethasone as adjunctive therapy with antibiotics can shorten the number of days of treatment with intravenous antibiotics.

### Number of days of oral antibiotic treatment

Two studies provided the number of days of oral antibiotics. No significant heterogeneity was found, and a fixed model was used (*I*^2^=5.9%, *P*=0.303). The results show 85 cases in the experimental, and 87 in the control groups. There was a significant difference in the number of days of oral antibiotics between the experimental and the control groups (MD = −1.658, 95% CI: −2.539 to −0.777, *P*=0.001, [Figure 6](#f6-dddt-12-2277){ref-type="fig"}). The present meta-analysis shows that adjunctive dexamethasone could shorten the number of days of oral antibiotic treatment.

Discussion
==========

A vast array of pathogenic organisms has been identified as causing SA. The most common types of bacteria are the Gram-positive cocci, such as Staphylococcus and Streptococcus.[@b17-dddt-12-2277],[@b18-dddt-12-2277] In fact, *Kingella kingae*, formerly called Moraxella kingae, is increasingly becoming an important pathogen of SA in patients \<3 years of age.[@b1-dddt-12-2277] A recent study suggests that 82% of SA cases are caused by *K. kingae* in patients \<4 years of age.[@b19-dddt-12-2277]--[@b21-dddt-12-2277] Therefore, antibiotic application based on the organisms is the key to the treatment of SA. Although previous studies have demonstrated that adjunctive corticosteroids could improve the outcomes of severe sepsis, pneumonia, bacterial meningitis, and acute pyelonephritis,[@b9-dddt-12-2277],[@b22-dddt-12-2277]--[@b25-dddt-12-2277] the efficacy and safety of adjunctive corticosteroids in SA were controversial. To our knowledge, this is the first quantitative meta-analysis to evaluate the efficacy of corticosteroids as adjunctive therapy with antibiotics in the treatment of children with SA.

Using plasma-CRP as an useful indicator of assessing anti-inflammatory therapeutic effect has been confirmed by other studies.[@b26-dddt-12-2277],[@b27-dddt-12-2277] The measurement of CRP as a useful index for assessing the response to SA treatment was initially performed in animal models.[@b8-dddt-12-2277] The first studies were conducted in humans in 2003. Odio et al[@b11-dddt-12-2277] observed that the CRP in dexamethasone-treated patients was reduced significantly faster than in control patients and reported that adjunctive dexamethasone could shorten the duration of symptoms and reduce residual dysfunction at the end of the treatment period and during follow-up. It is noteworthy that the results were similar to those reported recently by Harel et al.[@b16-dddt-12-2277] The present meta-analysis shows a shorter time to a decrease in CRP to normal levels in the dexamethasone group. Sakiniene et al[@b8-dddt-12-2277] concluded that the reason for the quicker drop of CRP could be explained by the inhibitory effect of the corticosteroids on T- and B-cell proliferation and differentiation, leading to a decrease in cytokine production.

The duration of antibiotic treatment and hospitalization was dependent on the clinical signs of improvement, absence of pathogenic bacteria of joint fluid, and a normal CRP. A consistent finding between the study by Fogel et al[@b14-dddt-12-2277] and our meta-analysis is a significant reduction in the duration of intravenous and oral antibiotic treatment. The children in the dexamethasone group experienced a significantly faster and more favorable clinical response than controls did and thus were switched to oral therapy at an earlier time. Furthermore, Fogel et al[@b14-dddt-12-2277] noted that the number of days of hospitalization was 8.0 and 10.7 days in the dexamethasone and placebo groups, respectively. Similar results were reported in other included studies and the present meta-analysis.

We were also concerned about the existence of adverse reactions, relapse, and sequelae since corticosteroids may hide the symptoms of infection and thereby lead to antibiotic treatment that is too short. Fogel et al[@b14-dddt-12-2277] reported four cases of relapse of transient symptoms less than a week after completing the corticosteroids course. At 12 months of follow-up, Odio et al[@b11-dddt-12-2277] reported that 1 patient in the dexamethasone group had hip involvement with impaired angles of movement, limping, and shortening of the affected extremity, and 13 patients in the placebo group had dysfunction. Although no included study documented adverse events associated with corticosteroids, larger sample sizes and longer follow-up RCTs are further needed.

This study has the following limitations: 1) only three RCTs and one RCS were included in the present meta-analysis and the sample sizes were relatively small; 2) the included studies were short of some data, and we failed to perform a meta-analysis, such as functional score; and 3) follow-up was relatively short, which may lead to an underestimation of complications.

Conclusion
==========

The present meta-analysis base points strongly toward a beneficial effect for corticosteroids in SA. Corticosteroids as adjunctive therapy with antibiotics in the treatment of children with SA could shorten the number of days of hospitalization, intravenous and oral antibiotics treatment, as well as the number of days to normalization of CRP. Therefore, we recommend corticosteroids as adjuvant therapy with antibiotics in the treatment of children with SA.
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###### 

The results of meta-analysis

  Outcome                                     Studies   Groups (D/P)   Overall effect   Heterogeneity                     
  ------------------------------------------- --------- -------------- ---------------- ------------------ ------- ------ -------
  Days of hospitalization                     2         56/120         −4.226           −4.785 to −3.667   0.000   0.0    0.524
  Days to normalization of CRP                3         111/177        −3.075           −3.362 to −2.788   0.000   0.0    0.728
  Days of intravenous antibiotics treatment   3         111/177        −3.593           −4.825 to −2.361   0.000   61.8   0.073
  Days of oral antibiotics treatment          2         85/83          −1.658           −2.539 to −0.777   0.000   5.9    0.303

**Abbreviations:** CRP, C-reactive protein; D, dexamethasone; P, placebo.

###### 

Quality assessment score of the included studies

  Quality assessment for non-randomized trials          Fogel et al 2015[@b14-dddt-12-2277]
  ----------------------------------------------------- -------------------------------------
  A clearly stated aim                                  2
  Inclusion of consecutive patients                     2
  Prospective data collection                           0
  Endpoints appropriate to the aim of the study         2
  Unbiased assessment of the study endpoint             2
  A follow-up period appropriate to the aims of study   2
  Less than 5% loss to follow-up                        0
  Prospective calculation of the sample size            0
  An adequate control group                             2
  Contemporary groups                                   2
  Baseline equivalence of groups                        2
  Adequate statistical analyses                         2

###### 

The characteristics of included studies

  Study                                 Sample size   Age   Glucocorticoid                                                                                          Dose            Follow-up                
  ------------------------------------- ------------- ----- ------------------------------------------------------------------------------------------------------- --------------- ------------------------ -------------------------------------------------
  Harel et al 2011[@b16-dddt-12-2277]   24            25    34.74[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}/31.13[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}   Dexamethasone   0.15 mg/kg Q6 h 4 days   12[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}
  Odio et al 2003[@b11-dddt-12-2277]    61            62    5.55[‡](#tfn3-dddt-12-2277){ref-type="table-fn"}/5.81[‡](#tfn3-dddt-12-2277){ref-type="table-fn"}       Dexamethasone   0.20 mg/kg Q6 h 4 days   12[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}
  Arti et al 2014[@b10-dddt-12-2277]    30            30    8.06[‡](#tfn3-dddt-12-2277){ref-type="table-fn"}/8.00[‡](#tfn3-dddt-12-2277){ref-type="table-fn"}       Dexamethasone   0.15 mg/kg Q6 h 4 days   NS
  Fogel et al 2015[@b14-dddt-12-2277]   26            90    20.6[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}/27.4[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}     Dexamethasone   0.15 mg/kg Q6 h 4 days   12[\*](#tfn2-dddt-12-2277){ref-type="table-fn"}

**Notes:**

Months;

Year.

**Abbreviations:** D, dexamethasone; P, placebo; NS, not significant.
